Shandong Sanyuan Biotechnology Co.Ltd. (301206) — Working Capital to Net Assets Ratio
Shandong Sanyuan Biotechnology Co.Ltd. (301206) has a Working Capital to Net Assets ratio of 50.1% as of September 2025. Working capital of CN¥2.16 Billion (current assets of CN¥2.27 Billion minus current liabilities of CN¥107.70 Million) is measured against net assets of CN¥4.31 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shandong Sanyuan Biotechnology Co.Ltd. net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shandong Sanyuan Biotechnology Co.Ltd. Working Capital to Net Assets (2013–2024)
This chart shows how Shandong Sanyuan Biotechnology Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 50.1%, reflecting working capital of CN¥2.16 Billion against net assets of CN¥4.31 Billion CNY. Check 301206 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Shandong Sanyuan Biotechnology Co.Ltd. (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Sanyuan Biotechnology Co.Ltd. from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 301206 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 70.0% | CN¥3.14 Billion | CN¥4.49 Billion | CN¥3.39 Billion | CN¥243.67 Million | ▲ +67.9 pp |
| 2023 | 2.2% | CN¥97.62 Million | CN¥4.54 Billion | CN¥321.81 Million | CN¥224.20 Million | ▼ -7.8 pp |
| 2022 | 10.0% | CN¥461.86 Million | CN¥4.62 Billion | CN¥669.37 Million | CN¥207.51 Million | ▼ -13.0 pp |
| 2021 | 23.0% | CN¥240.81 Million | CN¥1.05 Billion | CN¥805.62 Million | CN¥564.81 Million | ▼ -0.5 pp |
| 2020 | 23.5% | CN¥119.78 Million | CN¥509.91 Million | CN¥378.67 Million | CN¥258.89 Million | ▲ +3.5 pp |
| 2019 | 20.0% | CN¥69.52 Million | CN¥348.15 Million | CN¥238.97 Million | CN¥169.46 Million | ▲ +3.8 pp |
| 2018 | 16.2% | CN¥29.08 Million | CN¥179.52 Million | CN¥128.11 Million | CN¥99.03 Million | ▼ -1.4 pp |
| 2017 | 17.6% | CN¥20.38 Million | CN¥115.81 Million | CN¥84.74 Million | CN¥64.36 Million | ▼ -18.3 pp |
| 2016 | 35.9% | CN¥31.11 Million | CN¥86.64 Million | CN¥71.55 Million | CN¥40.44 Million | ▲ +39.4 pp |
| 2015 | -3.5% | CN¥-1.49 Million | CN¥42.30 Million | CN¥23.15 Million | CN¥24.64 Million | ▲ +5.6 pp |
| 2014 | -9.1% | CN¥-2.42 Million | CN¥26.60 Million | CN¥26.98 Million | CN¥29.40 Million | ▼ -47.1 pp |
| 2013 | 38.0% | CN¥9.92 Million | CN¥26.08 Million | CN¥27.63 Million | CN¥17.71 Million | — |